中國興業控股(00132.HK)中期溢利5123.7萬港元 同比增長10.01%
格隆匯8月30日丨中國興業控股(00132.HK)公吿,截至2023年6月30日止六個月,公司總收入4.14億港元,同比增長17.11%;期間溢利5123.7萬港元,同比增長10.01%;每股盈利港幣0.52仙。
集團持續向構建南海區機構、社區及居家三級養老體系方向發展,本集團順利接收各南海鎮街公辦養老機構,成為全佛山市規模最大的機構養老品牌。於2023年6月30日,共有機構養老牀位2,200張及入住率為79%,與2022年12月31日相比,養老牀位增加約5%,但入住率輕微下降4%;而現有康復及護理病牀則合共300張,平均病牀使用率達78%,比去年底上升了8%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.